A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients with Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Jina Pharmaceuticals
Most Recent Events
- 21 Mar 2025 Planned End Date changed from 31 Jul 2024 to 31 Dec 2025.
- 21 Mar 2025 Planned primary completion date changed from 31 May 2024 to 31 May 2025.
- 09 Feb 2023 Planned End Date changed from 31 May 2022 to 31 Jul 2024.